公开(公告)号：US20200164024A1

公开(公告)日：2020-05-28

申请号：US16695843

申请日：2019-11-26

申请人： NOVARTIS AG

发明人： Karin BRINER ,  Brian Addison DECHRISTOPHER ,  Alec Nathanson FLYER ,  Andrei Alexandrovich GOLOSOV ,  Philipp GROSCHE ,  Eugene Yuejin LIU ,  Justin Yik Ching MAO ,  Lauren Gilchrist MONOVICH ,  Tajesh Jayprakash PATEL ,  Carina Cristina SANCHEZ ,  Liansheng SU ,  Lihua YANG ,  Rui ZHENG

IPC分类号： A61K38/12 ,  A61K45/06 ,  C07K5/12

摘要： The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

公开(公告)号：US20230089867A1

公开(公告)日：2023-03-23

申请号：US17296895

申请日：2019-11-26

申请人： Novartis AG

发明人： Christopher BECKER ,  Brian Addison DECHRISTOPHER ,  Alec Nathanson FLYER ,  Adam FRIEDMAN ,  Christian GAMPE ,  Andrei Alexandrovich GOLOSOV ,  Philipp GROSCHE ,  Tyler HARRISON ,  Qian LIU ,  Eugene Yuejin LIU, I ,  Justin Yik Ching MAO ,  Lauren Gilchrist MONOVICH ,  Tajesh Jayprakash PATEL ,  Carina Cristina SANCHEZ ,  Liansheng SU ,  Lihua YANG ,  Rui ZHENG

IPC分类号： C07K7/56

摘要： The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6′, R7, R7′, R8, R9, R9′, R10, R11, R12, and n are described herein.

公开(公告)号：US20210252103A1

公开(公告)日：2021-08-19

申请号：US17200471

申请日：2021-03-12

申请人： NOVARTIS AG

发明人： Karin BRINER ,  Brian Addison DECHRISTOPHER ,  Alec Nathanson FLYER ,  Andrei Alexandrovich GOLOSOV ,  Philipp GROSCHE ,  Eugene Yuejin LIU ,  Justin Yik Ching MAO ,  Lauren Gilchrist MONOVICH ,  Tajesh Jayprakash PATEL ,  Liansheng SU ,  Lihua YANG ,  Rui ZHENG

IPC分类号： A61K38/12 ,  A61K45/06 ,  C07K5/12

摘要： The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

公开(公告)号：US20240336598A1

公开(公告)日：2024-10-10

申请号：US18589841

申请日：2024-02-28

申请人： Novartis AG

发明人： Daniela ANGST ,  Philippe Bolduc ,  Matthew William Carson ,  Atwood Kim CHEUNG ,  Véronique Darsigny ,  Xiang GAO ,  Viktor HORNAK ,  Keith JENDZA ,  Rajesh KARKI ,  Ajay Kumar LAL ,  Gang LIU ,  Justin Yik Ching MAO ,  Jeffrey M. McKENNA ,  Erik MEREDITH ,  Muneto MOGI ,  Vivek RAUNIYAR ,  Liansheng SU ,  Ritesh TICHKULE ,  Shuangxi WANG ,  Chun ZHANG ,  Liang ZHAO ,  Rui ZHENG

IPC分类号： C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

摘要： The disclosure relates to a compound of Formula (I):




or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.